{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:45:21Z","timestamp":1792226721546,"version":"4.4.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-02020-3","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T19:32:27Z","timestamp":1767036747000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Bone metastases in advanced urothelial carcinoma patients receiving enfortumab vedotin: A Real-World study from the ARON-2EV project"],"prefix":"10.1007","volume":"26","author":[{"given":"Alessandro","family":"Rizzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zin W.","family":"Myint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ciccimarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Zgura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc R.","family":"Matrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"B\u00fcttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindrich","family":"Kopecky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejo Rodriguez","family":"Vida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimma","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oronzo","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Hoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Formisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandr","family":"Poprach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Kucharz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Colomba","family":"Comes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Bove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarita","family":"Fanizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Massafra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Cazzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Sabino Marques","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Mollica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Massari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier Molina","family":"Cerrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"issue":"24","key":"2020_CR1","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.7150\/jca.28706","volume":"9","author":"C Zhang","year":"2018","unstructured":"Zhang C, Liu L, Tao F, Guo X, Feng G, Chen F, et al. Bone metastases pattern in newly diagnosed metastatic bladder cancer: a population-based study. J Cancer. 2018;9(24):4706\u201311.","journal-title":"J Cancer"},{"issue":"9","key":"2020_CR2","doi-asserted-by":"publisher","first-page":"e0183835","DOI":"10.1371\/journal.pone.0183835","volume":"12","author":"P Huang","year":"2017","unstructured":"Huang P, Lan M, Peng AF, Yu QF, Chen W, Liu ZL, Liu JM, Huang SH. Serum calcium, alkaline phosphatase, and hemoglobin as risk factors for bone metastases in bladder ancer. PLoS ONE. 2017;12(9):e0183835.","journal-title":"PLoS ONE"},{"issue":"1","key":"2020_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2214\/AJR.10.5036","volume":"196","author":"AB Shinagare","year":"2011","unstructured":"Shinagare AB, Ramaiya NH, Jagannathan JP, Fennessy FM, Taplin ME, Van den Abbeele A. Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor. AJR Am J Roentgenol. 2011;196(1):117\u201322.","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"2020_CR4","first-page":"203","volume":"18","author":"AN Taher","year":"2006","unstructured":"Taher AN, Kotb MH. Bone metastases in muscle-invasive bladder cancer. J Egypt Natl Canc Inst. 2006;18(3):203\u20138. PMID: 17671529.","journal-title":"J Egypt Natl Canc Inst"},{"key":"2020_CR5","doi-asserted-by":"crossref","unstructured":"Alqaisi HA, Stecca C, Veitch ZW, Riromar J, Kaiser J, Fallah-Rad N, Jiang DM, North S, Samnani S, Alimohamed N, Sridhar SS. The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy. Ther Adv Med Oncol. 2022 May;1:1417588359221094879.","DOI":"10.1177\/17588359221094879"},{"issue":"2","key":"2020_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.clgc.2021.12.008","volume":"20","author":"D Raggi","year":"2022","unstructured":"Raggi D, Giannatempo P, Marandino L, Pierantoni F, Maruzzo M, Lipari H, Banna GL, et al. Role of bone metastases in patients receiving immunotherapy for pre-treated urothelial carcinoma: the multicenter, retrospective meet-URO1 bone study. Clin Genitourin Cancer. 2022;20(2):155\u201364.","journal-title":"Clin Genitourin Cancer"},{"issue":"10","key":"2020_CR7","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1200\/JCO.19.02044","volume":"38","author":"J Rosenberg","year":"2020","unstructured":"Rosenberg J, Sridhar S, Zhang J, Smith D, Ruether D, Flaig TW, Baranda J, et al. EV-101: A phase I study of single-agent enfortumab Vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma. J Clin Oncol. 2020;38(10):1041\u20139.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2020_CR8","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","volume":"34","author":"JE Rosenberg","year":"2023","unstructured":"Rosenberg JE, Powles T, Sonpavde GP, Loriot Y, Duran I, Lee JL, et al. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma. Ann Oncol. 2023;34(11):1047\u201354.","journal-title":"Ann Oncol"},{"issue":"3","key":"2020_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.euo.2024.02.010","volume":"7","author":"DJ Benjamin","year":"2024","unstructured":"Benjamin DJ, Rezazadeh Kalebasty A, Prasad V. The overall survival benefit in EV-302: is enfortumab vedotin plus pembrolizumab the new frontline standard of care for metastatic urothelial carcinoma? Eur Urol Oncol. 2024;7(3):313\u20135. https:\/\/doi.org\/10.1016\/j.euo.2024.02.010.","journal-title":"Eur Urol Oncol"},{"issue":"10","key":"2020_CR10","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.annonc.2025.05.536","volume":"36","author":"TB Powles","year":"2025","unstructured":"Powles TB, Van der Heijden MS, Loriot Y, Bedke J, Valderrama BP, Iyer G, et al. Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial. Ann Oncol. 2025;36(10):1212\u20139. https:\/\/doi.org\/10.1016\/j.annonc.2025.05.536.","journal-title":"Ann Oncol"},{"issue":"8","key":"2020_CR11","doi-asserted-by":"publisher","first-page":"105544","DOI":"10.1016\/j.esmoop.2025.105544","volume":"10","author":"MS van der Heijden","year":"2025","unstructured":"van der Heijden MS, Powles T, Gupta S, Loriot Y, Galsky MD, Valderrama BP, et al. Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma. ESMO Open. 2025;10(8):105544. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105544. (Epub 2025 Aug 11. PMID: 40795788; PMCID: PMC12361773).","journal-title":"ESMO Open"},{"key":"2020_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2021.100405","volume":"31","author":"M Stellato","year":"2021","unstructured":"Stellato M, Santini D, Cursano MC, Foderaro S, Tonini G, Procopio G. Bone metastases from urothelial carcinoma. The dark side of the moon. J Bone Oncol. 2021;31:100405. https:\/\/doi.org\/10.1016\/j.jbo.2021.100405.","journal-title":"J Bone Oncol"},{"issue":"1","key":"2020_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3233\/BLC-200377","volume":"7","author":"AA Nelson","year":"2021","unstructured":"Nelson AA, Cronk RJ, Lemke EA, Szabo A, Khaki AR, Diamantopoulos LN, Grivas P, Nezami BG, MacLennan GT, Zhang T, Hoimes CJ. Early bone metastases are associated with worse outcomes in metastatic urothelial carcinoma. Bladder Cancer. 2021;7(1):33\u201342. PMID: 38993215; PMCID: PMC11181800.","journal-title":"Bladder Cancer"},{"issue":"2","key":"2020_CR14","doi-asserted-by":"publisher","first-page":"e483","DOI":"10.1016\/j.clgc.2017.10.012","volume":"16","author":"A Necchi","year":"2018","unstructured":"Necchi A, Pond GR, Pal SK, Agarwal N, Bowles DW, Plimack ER, Yu EY, Ladoire S, Baniel J, Crabb S, Niegisch G, Srinivas S, Berthold DR, Rosenberg JE, Powles T, Bamias A, Harshman LC, Bellmunt J, Galsky MD. Bone metastases as the only metastatic site in patients with urothelial carcinoma: focus on a special patient population. Clin Genitourin Cancer. 2018;16(2):e483\u201390.","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"2020_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2214\/AJR.10.5036","volume":"196","author":"AB Shinagare","year":"2011","unstructured":"Shinagare AB, Ramaiya NH, Jagannathan JP, Fennessy FM, Taplin ME, Van den Abbeele AD. Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor. AJR Am J Roentgenol. 2011;196(1):117\u201322.","journal-title":"AJR Am J Roentgenol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-02020-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-02020-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-02020-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T03:53:52Z","timestamp":1767671632000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-02020-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2020"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-02020-3","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Francesco Massari has received research support and\/or honoraria from Advanced Accelerator Applications, Astellas, Astra Zeneca, Bayer, BMS, Janssen, Ipsen, Merck, MSD, Pfizer outside the submitted work.\u00a0Fernando Sabino Marques Monteiro (ORCID: 0000-0002-6621-8251): has received research support provided by MSD and Foundation Medicine. Honoraria from Janssen, Ipsen, BMS, Novartis, AstraZeneca, Bayer, Astellas and MSD. Travel expenses by Novartis, Bayer, ADIUM, Merck and Johson & Johson. Consulting or Advisory Role from Novartis. Ownership: BIO, Brazilian Information Oncology. All are unrelated to this study.\u00a0","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol was approved on 28 September 2023 by the Ethical Committee of the coordinating center (Marche Region, Italy \u2013 no. 2022 39\/7875) and by the Institutional Review Boards of participating centers. The study was conducted according to Good Clinical Practice (GCP) and International Ethical Guidelines for Biomedical Research, and the protocol has been designed with the ethical principles laid out in the Declaration of Helsinki on human experimentation. The authors affiliated to Istituto Tumori \u2018Giovanni Paolo II\u2019, IRCCS, Bari are responsible for the views expressed in this article, which do not necessarily represent the ones of the Institute.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"\u2018Informed consent\u2019 for publication was collected for all the patients involved in the study, except for patients who are dead or not reachable, as it is a retrospective study (Garante della Privacy n. 9\/2016 in data 15 Dicember 2016).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"75"}}